Daewha Sees Promise In Herbal-Derived Alzheimer’s Candidate
This article was originally published in PharmAsia News
In a rare move, South Korea's Daehwa Pharm is progressing the development of a herbal-derived therapy for Alzheimer's disease, a sector where many pharma firms have been conducting R&D but have faced challenges and failures.
You may also be interested in...
Anti-beta amyloid antibodies from Lilly, Biogen Idec and Roche took center stage at the recent Alzheimer’s Association International Congress, but as a new PhRMA analysis shows, getting to the development finish line is rare – with 30 failures for every one success.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.